Divi’s Laboratories vs Laurus Labs vs Syngene International: Which Stock Should You Track
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Market
Divi’s Laboratories PE 84.81, mkt cap Rs 2,48,054 crore. Laurus Labs PE 99.36, mkt cap Rs 1,08,338 crore. Syngene International PE 69.05, mkt cap Rs 15,247 crore.
Quick Answer
Divi’s Laboratories vs Laurus Labs vs Syngene International is a side-by-side comparison of three companies from the Pharma CDMO and API space. On this comparison, Divi’s Laboratories carries a market capitalisation of about Rs 2,48,054 crore against Rs 1,08,338 crore for Laurus Labs and Rs 15,247 crore for Syngene International, with return on equity of 15.32%, 16.77% and 7.76% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Divi’s Laboratories vs Laurus Labs vs Syngene International starts with the core numbers most investors compare within the Pharma CDMO and API segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Pharma CDMO and API bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Divi’s Laboratories, Laurus Labs and Syngene International: Company Overview
Divi’s Laboratories is a listed Indian company in the Pharma CDMO and API space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Laurus Labs is a listed Indian company in the Pharma CDMO and API space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Syngene International is a listed Indian company in the Pharma CDMO and API space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Divi’s Laboratories vs Laurus Labs vs Syngene International: Valuation and Profitability Snapshot
| Metric | Divi’s Laboratories | Laurus Labs | Syngene International |
|---|---|---|---|
| Market Cap (approx.) | Rs 2,48,054 crore | Rs 1,08,338 crore | Rs 15,247 crore |
| PE Ratio (TTM) | 84.81 | 99.36 | 69.05 |
| PB Ratio | 14.80 | 20.44 | 3.15 |
| Return on Equity (ROE) | 15.32% | 16.77% | 7.76% |
| EPS (TTM, Rs) | 110.18 | 20.18 | 5.47 |
| Dividend Yield | 0.32% | 0.10% | 0.33% |
| Debt to Equity | 0.00 | 0.48 | 0.09 |
| Book Value per Share (Rs) | 631.38 | 98.09 | 119.90 |
Check the Univest Screener for Live Data
On valuation, Divi’s Laboratories trades at a PE of 84.81 and a PB of 14.80, Laurus Labs at a PE of 99.36 and a PB of 20.44, while Syngene International trades at a PE of 69.05 and a PB of 3.15. On return on equity, the three post 15.32%, 16.77% and 7.76% respectively, and on dividend yield they stand at 0.32%, 0.10% and 0.33%.
Divi’s Laboratories vs Laurus Labs vs Syngene International: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Divi’s Laboratories | Rs 3,144.00 crore | Rs 902.00 crore | +24.3% | +5.3% |
| Laurus Labs | Rs 2,035.49 crore | Rs 361.99 crore | +28.8% | +11.6% |
| Syngene International | Rs 761.30 crore | Rs -9.00 crore | -14.7% | -28.1% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Divi’s Laboratories, Laurus Labs and Syngene International live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma cdmo and api names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Divi’s Laboratories vs Laurus Labs vs Syngene International highlights how differently three companies in the same pharma cdmo and api segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Divi’s Laboratories vs Laurus Labs vs Syngene International
What is the market cap difference between Divi’s Laboratories, Laurus Labs and Syngene International?
Ans. As of September 2026, Divi’s Laboratories has a market cap of approximately Rs 2,48,054 crore, Laurus Labs is at approximately Rs 1,08,338 crore, and Syngene International is at approximately Rs 15,247 crore.
Which of the three has the highest PE ratio?
Ans. Among Divi’s Laboratories, Laurus Labs and Syngene International, the PE ratios stand at 84.81, 99.36 and 69.05 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Divi’s Laboratories, Laurus Labs and Syngene International post ROE of 15.32%, 16.77% and 7.76% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Divi’s Laboratories, Laurus Labs and Syngene International carry dividend yields of 0.32%, 0.10% and 0.33% respectively.
What is the debt to equity ratio for Divi’s Laboratories, Laurus Labs and Syngene International?
Ans. Divi’s Laboratories carries a debt to equity of 0.00, Laurus Labs of 0.48, and Syngene International of 0.09.
Which of the three trades at the highest price to book value?
Ans. Divi’s Laboratories, Laurus Labs and Syngene International trade at price to book ratios of 14.80, 20.44 and 3.15 respectively.
Is one of Divi’s Laboratories, Laurus Labs or Syngene International better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
